NUTX 8-K: SEC filing

Nutex Health

Filed with the SEC on · accession 0001628280-26-071003

NUTX filed a 8-K (current report) with the SEC on Nov 5, 2026. Nutex Health reported Q3 2026 financial results with net income of $40.2 million and diluted EPS of $5.71, down from $55.4 million and $7.76 in Q3 2025, while nine-month net income rose 159% to $152.9 million.

Summary of the filing

Nutex Health reported Q3 2026 financial results with net income of $40.2 million and diluted EPS of $5.71, down from $55.4 million and $7.76 in Q3 2025, while nine-month net income rose 159% to $152.9 million. Total revenue declined 18.7% in Q3 and 10.9% for the nine months, though operating cash flow remained strong at $188.1 million.

Key details

Q3 2026 net income attributable to Nutex Health$40.2M
Q3 2026 diluted EPS$6
Q3 2025 net income attributable to Nutex Health$55.4M
Q3 2025 diluted EPS$8
Nine-month 2026 net income attributable to Nutex Health$152.9M
Nine-month 2026 diluted EPS$22
Nine-month 2025 net income attributable to Nutex Health$59.0M
Nine-month 2025 diluted EPS$9
Q3 2026 Adjusted EBITDA attributable to Nutex Health$63.9M
Q3 2025 Adjusted EBITDA attributable to Nutex Health$98.5M
Nine-month 2026 Adjusted EBITDA attributable to Nutex Health$211.4M
Nine-month 2025 Adjusted EBITDA attributable to Nutex Health$243.0M
Q3 2026 total revenue$217.6M
Q3 2025 total revenue$267.8M
Nine-month 2026 total revenue$644.9M
Nine-month 2025 total revenue$723.6M
Nine-month 2026 net cash provided by operating activities$188.1M
Nine-month 2025 net cash provided by operating activities$177.7M
Cash and cash equivalents as of September 30, 2026$249.9M
Long-term debt, net as of September 30, 2026$34.2M
Non-cash reduction to contract services expense$52.3M
Total cost of arbitration for nine months ended September 30, 2026$61.4M
Total stock-based compensation expense for nine months ended September 30, 2026$6.4M
IssuerNutex Health Inc.
Contract counterpartyHaloMD
Chief financial officerJon Bates
Chairman and chief executive officerTom Vo

✦ Ask GOAX AI about this filing — what it means for NUTX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for NUTX?

Click here

Frequently asked questions

What did NUTX file with the SEC on Nov 5, 2026?

NUTX filed a 8-K (SEC filing). Nutex Health reported Q3 2026 financial results with net income of $40.2 million and diluted EPS of $5.71, down from $55.4 million and $7.76 in Q3 2025, while nine-month net income rose 159% to $152.9 million. Total revenue declined 18.7% in Q3 and 10.9% for the nine months, though operating cash flow remained strong at $188.1 million.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other NUTX SEC filings

Get alerts when NUTX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days